Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;12(7):1014-1022.
doi: 10.1111/1759-7714.13814. Epub 2021 Mar 4.

Prognostic factors for progression-free and overall survival in malignant pleural mesothelioma

Jordi Guzmán-Casta  1 , Sonia Carrasco-CaraChards  2 , Jorge Guzmán-Huesca  3 , Carla Paola Sánchez-Ríos  1 , Rodrigo Riera-Sala  1 , José Fabián Martínez-Herrera  1 , Erika Sagrario Peña-Mirabal  4 , Diana Bonilla-Molina  5 , Jorge Arturo Alatorre-Alexander  1 , Luis Manuel Martínez-Barrera  1 , Jerónimo Rafael Rodríguez-Cid  1
Affiliations

Prognostic factors for progression-free and overall survival in malignant pleural mesothelioma

Jordi Guzmán-Casta et al. Thorac Cancer. 2021 Apr.

Abstract
in English, Spanish

Background: Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced disease at the time of presentation. Exposure to asbestos is the most important risk factor for malignant pleural mesothelioma. Mesothelioma is a neoplasia with a long preclinical stage that can span from 15 to 40 years.

Methods: This was a descriptive, observational, retrospective study of 136 patients with a confirmed diagnosis of mesothelioma, which compared histological subtypes, immunohistochemical biomarkers, concomitant chronic degenerative diseases, tobacco use, age at the time of diagnosis, clinical stage and chemotherapy agents used or other treatments such as radiotherapy and surgery to identify all the factors that impact in the prognosis of overall survival (OS) and progression-free survival (PFS).

Results: A total of 136 patients were included in the study. In the total study population, 84 patients were male (61.8%) and 52 were female (38.2%). Median PFS was nine months (95% confidence interval [CI]: 8.4-9.5 months) and median OS was 12 months (95% CI: 11.3-12.6). The results indicated that the most determining prognostic factors for OS and PFS were cell differentiation measured by immunohistochemical biomarkers, the treatment chosen, and that RECIST was the most significant in the evaluation of patient response to treatment.

Conclusions: Malignant pleural mesothelioma is a cancer with a poor prognosis usually diagnosed at an advanced stage of disease. Our study revealed that the prognostic factors for OS and PS were cell differentiation, the treatment chosen and RECIST.

Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis where the majority of patients already have advanced disease at the time of presentation. Mesothelioma is a neoplasia with a long preclinical stage that can span from 15 to 40 years. The median PFS in this study was nine months and median OS was 12 months. The most determining prognostic factors for OS and PFS were cell differentiation measured by immunohistochemical biomarkers, the treatment chosen, with RECIST being the most significant.

Keywords: Malignant pleural mesothelioma; overall survival; prognostic factors; progression-free survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival (OS).
Figure 2
Figure 2
Progression‐free survival (PFS)
Figure 3
Figure 3
Overall survival (OS) with the chemotherapy regimens used. (formula image) Pemetrexed/Cisplatin, (formula image) Pemetrexed/Carboplatin, (formula image) Gemcitabine/Carboplatin, (formula image) Gemcitabine, (formula image) Gemcitabine/Cisplatin.
Figure 4
Figure 4
Progression‐free survival (PFS) with the chemotherapy regimens used. (formula image) Pemetrexed/Cisplatin, (formula image) Pemetrexed/Carboplatin, (formula image) Gemcitabine/Carboplatin, (formula image) Gemcitabine, (formula image) Gemcitabine/Cisplatin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kindler H, Ismaila N, Armato SG 3rd et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical practice guideline. J Clin Oncol 2018; 36: 1343–73. - PMC - PubMed
    1. Rusch VW, Giroux D, Kennedy C et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012; 7: 1631–9. - PubMed
    1. Serna Camancho ME, Cortés Cárdenas SA. Mesotelioma pleural maligno. Gamo 2012; 11: 29–34.
    1. Ortega‐Gutiérrez F. El gneis Novillo y rocas metamórficas asociadas en los cañones del Novillo y de La Peregrina, área de Ciudad Victoria, Tamaulipas. Univ Nac Auton Mex Inst Geol Rev 1978; 2: 19–30.
    1. Santoro A, O'brien M, Stahel RA et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the international expanded access program. J Thorac Oncol 2008; 3: 756–63. - PubMed

LinkOut - more resources